In a U.S. Securities and Exchange Commission (SEC) filing, Hyderabad, India-based Dr. Reddy’s Laboratories Ltd. has referred to a Consumer Product Safety Commission (CPSC) investigation into the company’s alleged failure to comply with special child-resistant packaging regulations under the Poison Prevention Packaging Act. While the company disagrees with the allegations “and is engaged in discussions with the CPSC regarding its compliance,” the agency’s intent to seek civil penalties and a Department of Justice investigation of similar issues under the Federal False Claims Act have led the drug maker to state, “[T]he Company cannot conclude that the likelihood of an unfavorable outcome is either probable or remote. . . . An unfavorable outcome in these matters could result in significant liabilities, which could have a material adverse effect on the Company.” See Dr. Reddy’s Laboratories Ltd. Form 6-K, August 19, 2014.